Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A prospective randomized trial designed to compare the efficacy and safety of Sirolimus coated balloon (SCB) versus paclitaxel coated balloon (DCB) in the treatment of femoropopliteal artery stenosis
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sirolimus-eluting balloon angioplasty | Experimental | Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery |
|
| Paclitaxel-eluting balloon angioplasty | Active Comparator | Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sirolimus-eluting balloon catheter | Device | Sirolimus-eluting balloon catheter designed and produced by Acotec |
|
| Measure | Description | Time Frame |
|---|---|---|
| The primary patency rate of target lesion at 12 months post-procedure | Defined as freedom from clinically driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4) | 12 months post-procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of device success | Defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP) | immediate post-procedure |
| Rate of clinically driven target lesion revascularization (CD-TLR) at 12 months post-procedure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guo Wei, MD | Contact | 010-66887329 | pla301dml@vip.sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Guo Wei, MD | Chinese PLA General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chinese PLA General Hospital | Recruiting | Beijing | Beijing Municipality | 100039 | China |
Not provided
| ID | Term |
|---|---|
| D058729 | Peripheral Arterial Disease |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Paclitaxel-eluting balloon catheter | Device | Paclitaxel-eluting balloon catheter (trade name:DHALIA) |
|
|
Defined as any reintervention at the target lesion due to symptoms or the following index: drop of ABI >20% or ABI >0.15 compared to the post-procedure ABI during 12 months post-procedure |
| 12 months post-procedure |
| The change of Rutherford class from baseline | Defined as change in target limb Rutherford class from baseline to 12 months | 12 months post-procedure |
| The change of ankle-brachial index (ABI) from baseline | Defined as change of target limb ABI from baseline to 12 months | 12 months post-procedure |
| Rate of composite safety endpoint | Defined a composite rate of device-related or procedure-related death, major target limb amputation (above-the-ankle amputation), clinically driven target lesion revascularization (CD-TLR) or target lesion thrombotic events through 30 days post- procedure | 30 days post-procedure |
| D002318 |
| Cardiovascular Diseases |
| D016491 | Peripheral Vascular Diseases |